BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 31364025)

  • 1. Pleotropic Roles of Autotaxin in the Nervous System Present Opportunities for the Development of Novel Therapeutics for Neurological Diseases.
    Herr DR; Chew WS; Satish RL; Ong WY
    Mol Neurobiol; 2020 Jan; 57(1):372-392. PubMed ID: 31364025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme.
    Tabuchi S
    Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autotaxin/Lysophosphatidic Acid Axis: From Bone Biology to Bone Disorders.
    Alioli C; Demesmay L; Peyruchaud O; Machuca-Gayet I
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological roles of lysophosphatidic acid signaling through its production by autotaxin.
    Okudaira S; Yukiura H; Aoki J
    Biochimie; 2010 Jun; 92(6):698-706. PubMed ID: 20417246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Therapeutic Applications for Inhibitors of Autotaxin, a Bioactive Lipid-Producing Lysophospholipase D, in Disorders Affecting the Nervous System.
    Herr DR; Ong JH; Ong WY
    ACS Chem Neurosci; 2018 Mar; 9(3):398-400. PubMed ID: 29457888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation.
    Trovato FM; Zia R; Napoli S; Wolfer K; Huang X; Morgan PE; Husbyn H; Elgosbi M; Lucangeli M; Miquel R; Wilson I; Heaton ND; Heneghan MA; Auzinger G; Antoniades CG; Wendon JA; Patel VC; Coen M; Triantafyllou E; McPhail MJ
    Hepatology; 2021 Aug; 74(2):907-925. PubMed ID: 33908067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Function and biological activities of the autotaxin-LPA axis].
    Li ZW; Zhao YR; Zhao C; Fu R; Li ZY
    Sheng Li Xue Bao; 2011 Dec; 63(6):601-10. PubMed ID: 22193457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autotaxin and chronic inflammatory diseases.
    Magkrioti C; Galaris A; Kanellopoulou P; Stylianaki EA; Kaffe E; Aidinis V
    J Autoimmun; 2019 Nov; 104():102327. PubMed ID: 31471142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the autotaxin - Lysophosphatidic acid receptor axis in cardiovascular diseases.
    Zhao Y; Hasse S; Zhao C; Bourgoin SG
    Biochem Pharmacol; 2019 Jun; 164():74-81. PubMed ID: 30928673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autotaxin inhibitors: a patent review.
    Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
    Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.
    Salgado-Polo F; Fish A; Matsoukas MT; Heidebrecht T; Keune WJ; Perrakis A
    J Biol Chem; 2018 Sep; 293(37):14312-14327. PubMed ID: 30026231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer.
    Barbayianni E; Kaffe E; Aidinis V; Kokotos G
    Prog Lipid Res; 2015 Apr; 58():76-96. PubMed ID: 25704398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).
    Sun Y; Zhang W; Evans JF; Floreani A; Zou Z; Nishio Y; Qi R; Leung PS; Bowlus CL; Gershwin ME
    Autoimmun Rev; 2016 Aug; 15(8):795-800. PubMed ID: 27019050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
    Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
    FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autotaxin-LPA-LPP3 Axis in Energy Metabolism and Metabolic Disease.
    Jose A; Kienesberger PC
    Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer.
    Teo K; Brunton VG
    Biochem J; 2014 Oct; 463(1):157-65. PubMed ID: 25195735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain.
    Ma L; Uchida H; Nagai J; Inoue M; Aoki J; Ueda H
    J Pharmacol Exp Ther; 2010 May; 333(2):540-6. PubMed ID: 20123931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Expression Regulation and Biological Function of Autotaxin.
    Zhang X; Li M; Yin N; Zhang J
    Cells; 2021 Apr; 10(4):. PubMed ID: 33921676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes.
    Sevastou I; Kaffe E; Mouratis MA; Aidinis V
    Biochim Biophys Acta; 2013 Jan; 1831(1):42-60. PubMed ID: 22867755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis.
    Orosa B; GarcĂ­a S; Conde C
    Eur J Pharmacol; 2015 Oct; 765():228-33. PubMed ID: 26297977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.